Of the 244 patients with GEJ adenocarcinoma, 122 (50%) were tested for PD-L1, 126 (52%) were tested for MMR/MSI, and 202 (83%) were tested for HER2 (Table 1 and Table S2). The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.